Attralus

Attralus company information, Employees & Contact Information

Explore related pages

Related company profiles:

Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Our proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.

Company Details

Employees
32
Address
Naples, Fl 34102, Us
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Technician jobs.
HQ
Naples, FL
Looking for a particular Attralus employee's phone or email?

Attralus Questions

News

Attralus Presents New Data on Its Pan-Amyloid Diagnostic Imaging Candidates at ASNC 2025 - GlobeNewswire

Attralus Presents New Data on Its Pan-Amyloid Diagnostic Imaging Candidates at ASNC 2025 GlobeNewswire

Attralus Presents New Data on Its Pan-Amyloid Diagnostic - GlobeNewswire

Attralus Presents New Data on Its Pan-Amyloid Diagnostic GlobeNewswire

Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA) - Yahoo Finance

Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at the XIX International Symposium on Amyloidosis (ISA) Yahoo Finance

Attralus Announces Enrollment of First Patient in Phase 3 - GlobeNewswire

Attralus Announces Enrollment of First Patient in Phase 3 GlobeNewswire

Attralus set for amyloidosis asset’s European orphan designations - Pharmaceutical Technology

Attralus set for amyloidosis asset’s European orphan designations Pharmaceutical Technology

A few months into his new role at Attralus, ex-Purdue chief Mark Timney leads the biotech to a $116M round - Endpoints News

A few months into his new role at Attralus, ex-Purdue chief Mark Timney leads the biotech to a $116M round Endpoints News

Amyloidosis biotech Attralus scores $116M for handful of treatments, imaging agent - Fierce Biotech

Amyloidosis biotech Attralus scores $116M for handful of treatments, imaging agent Fierce Biotech

Attralus Secures Investment to Transform Treatment for Patients with Systemic Amyloidosis - The University of Tennessee System

Attralus Secures Investment to Transform Treatment for Patients with Systemic Amyloidosis The University of Tennessee System

Attralus doses first subject in Phase I pan-amyloid removal therapy trial - Clinical Trials Arena

Attralus doses first subject in Phase I pan-amyloid removal therapy trial Clinical Trials Arena

FDA sees potential in new PET imaging agent for cardiac amyloidosis - Cardiovascular Business

FDA sees potential in new PET imaging agent for cardiac amyloidosis Cardiovascular Business

Attralus Shows Promise in Tackling Systemic Amyloidosis - Inside Precision Medicine

Attralus Shows Promise in Tackling Systemic Amyloidosis Inside Precision Medicine

AT-02, to clear amyloid deposits, named orphan drug by FDA - FAP News Today

AT-02, to clear amyloid deposits, named orphan drug by FDA FAP News Today

Attralus buys in brain shuttle tech to cross blood-brain barrier - The Pharma Letter

Attralus buys in brain shuttle tech to cross blood-brain barrier The Pharma Letter

Don't Miss a Beat: Navigating the ATTR-CM Care Landscape, With Ahmad Masri, MD - HCPLive

Don't Miss a Beat: Navigating the ATTR-CM Care Landscape, With Ahmad Masri, MD HCPLive

Ex-Purdue CEO Timney lands at amyloidosis biotech Attralus - Fierce Biotech

Ex-Purdue CEO Timney lands at amyloidosis biotech Attralus Fierce Biotech

Attralus Therapeutic AT-02 Receives Orphan Drug Designation - GlobeNewswire

Attralus Therapeutic AT-02 Receives Orphan Drug Designation GlobeNewswire

Ex-Purdue Pharma chief Mark Timney, named in dozens of opioid lawsuits, nabs another biotech CEO gig - Endpoints News

Ex-Purdue Pharma chief Mark Timney, named in dozens of opioid lawsuits, nabs another biotech CEO gig Endpoints News

Attralus Closes $56 Million Financing - GlobeNewswire

Attralus Closes $56 Million Financing GlobeNewswire

Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders - GlobeNewswire

Attralus and Ossianix Announce an Option and License Agreement using the TXP1 Brain Shuttle for Targeted Delivery of AT-04, a Pan-Amyloid Removal Therapeutic, for Neurodegenerative Disorders GlobeNewswire

Top Attralus Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant